Formulation development and characterization of galantamine hydrobromide extended-release capsules (8mg)

Alli Srija *, M. Sunitha Reddy, K. Hari Krishna and A. Vijay Reddy

Department of Pharmaceutics, Centre for Pharmaceutical Sciences, UCEST, Jawaharlal Nehru Technological University Hyderabad, Kukatpally, Hyderabad, 500085, Telangana, India.
 
Research Article
International Journal of Science and Research Archive, 2023, 10(02), 806–816.
Article DOI: 10.30574/ijsra.2023.10.2.1021
Publication history: 
Received on 01 November 2023; revised on 10 December 2023; accepted on 12 December 2023
 
Abstract: 
The aim of the present work is to develop extended-release capsules of Galantamine HBr (8mg)  and compare them  with the reference listed drug (Reminyl or Razadyne). The capsules were prepared using Pelletization technique and evaluated for preformulation characteristics, physical, and chemical parameters. The In-vitro dissolution studies were conducted using USP type II (paddle apparatus) in 900 ml of pH 6.5 phosphate buffer. Among all the formulations, F7 was found to be pharmaceutically equivalent to reference listed drug due to its similarity factor (f2= 96) in drug release profile. The F7 formulation was loaded for stability study and no change was observed, which indicates that the optimized F7 formulation was stable.
 
Keywords: 
Galantamine HBr; Reminyl or Razadyne; Pelletization technology; USP type II.
 
Full text article in PDF: 
 
Copyright information: 

Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0